10-Q: Recursion Pharma Q2 Loss Widens Amid R&D Surge

Recursion Pharmaceuticals reported a significant increase in net loss for Q2 2025, driven by higher R&D expenses and the integration of recent acquisitions, while advancing its AI-driven drug pipeline.

Summary

• Net loss for the six months ended June 30, 2025, significantly widened to $374.4 million, compared to $188.9 million for the same period in 2024, representing a 98% increase.
• Total revenue increased by 20% to $33.97 million for the six months ended June 30, 2025, up from $28.21 million in the prior year, primarily due to project timing from collaborations.
• Operating costs and expenses surged by 78% to $401.56 million for the six months ended June 30, 2025, compared to $225.09 million in 2024.
• Research and development expenses increased by 83% to $258.27 million, driven by $46.9 million in Tempus record purchases, $55.5 million from Exscientia operations, and increased personnel costs.
• General and administrative expenses rose by 60% to $101.30 million, influenced by $12.4 million from Exscientia, $12.9 million in salaries, and $8.4 million in severance expenses from a June 2025 workforce reduction.
• Cash and cash equivalents decreased to $525.11 million as of June 30, 2025, from $594.35 million at December 31, 2024.
• The company completed the acquisition of Exscientia plc in November 2024 for approximately $630.1 million, consisting of Class A shares and share-based awards.
• A workforce reduction of approximately 20% was announced in June 2025, incurring $8.4 million in severance expenses as of June 30, 2025, with total estimated charges of $9.3 million for the year.
• The company acquired full rights to the REC-102 (ENPP1 inhibitor) program from its joint venture with Rallybio in July 2025, positioning it as a potential first oral disease-modifying treatment for hypophosphatasia (HPP).
• An At-The-Market (ATM) offering with Citigroup Capital Markets Inc. was initiated in February 2025, with $104.1 million in net proceeds from 22.3 million shares sold as of June 30, 2025, and $395.9 million remaining available.

Sentiment

Score: 4

Explanation: The company reported significantly increased losses and cash burn, indicating a challenging financial period. However, strategic acquisitions, pipeline advancements, and ongoing collaborations provide a foundation for future growth, albeit with continued high R&D investment and a clear need for further capital.

Positives

• Total revenue increased by 20% for the six months ended June 30, 2025, demonstrating growth in strategic alliances.
• Achieved a $7 million milestone payment in Q2 2025 for an immunology program under the Sanofi collaboration, marking the fourth significant discovery milestone in 18 months.
• Advanced multiple internal pipeline programs, including initiating combination dose escalation for REC-617 (CDK7) and acquiring full rights to REC-102 (ENPP1 inhibitor) for hypophosphatasia.
• Continued progress in partnered discovery efforts with Sanofi, Roche & Genentech, Bayer, and Merck KGaA, with several programs advancing towards development candidate designation.
• Released the Boltz-2 open-source model, which has been downloaded by over 40,000 unique users, demonstrating the impact and adoption of the company's AI-enabled technologies.
• The Recursion OS 2.0 platform is actively expanding its Virtual Cell capabilities and integrating diverse cell types and patient datasets to strengthen programs and optimize recruitment.

Negatives

• Net loss significantly widened by 98% to $374.4 million for the six months ended June 30, 2025, compared to $188.9 million in the prior year.
• Operating costs and expenses increased substantially by 78%, driven by higher research and development and general and administrative costs.
• Cash used in operating activities increased to $208.38 million for the six months ended June 30, 2025, up from $184.52 million in the prior year, indicating increased cash burn.
• The company incurred a $4.5 million loss on the disposal of Exscientia GmbH and a $5.2 million lease termination fee for its Vienna facilities.
• A workforce reduction of approximately 20% was announced in June 2025, leading to $8.4 million in severance expenses and potential loss of institutional knowledge.
• A material weakness in internal control over financial reporting persists as of June 30, 2025, despite ongoing remediation efforts.

Risks

• Changes in tax laws or regulations, such as the One Big Beautiful Bill Act (OBBBA) and the Tax Cuts and Jobs Act (TCJA), could adversely affect the company's tax profile and financial performance.
• Increasing scrutiny and changing expectations regarding environmental, social, and governance (ESG) policies and practices may lead to additional costs, risks, or reputational damage.
• The recent cost reduction plan, including workforce reduction, may not achieve anticipated cost savings or operating efficiencies and could negatively impact employee morale and business operations.
• The company is subject to foreign currency exchange risk due to operations in the United Kingdom and Canada, though currently deemed insignificant.
• Uncertainty of clinical trial outcomes and the need for additional funding pose significant risks to the company's ability to advance drug candidates and continue operations.
• The company is dependent on third-party open-source software and cloud-based infrastructure, which could pose risks if not adequately managed.
• Potential intellectual property disputes and the ability to protect and enforce proprietary technology are ongoing risks in the highly competitive biotechnology market.

Future Outlook

The company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates, not expecting to generate significant revenue until successful completion of drug development milestones or collaborations. It believes existing cash and cash equivalents will fund operations for at least the next 12 months. The company aims to continue scaling its technology platform, adding more programs to its pipeline annually, and leveraging collaborations to accelerate drug discovery and development.

Management Comments

• Management believes the combination of the Recursion and Exscientia platforms and pipelines will position the company to be a leader in the AI-enabled drug discovery and development space.
• The company is on the precipice of demonstrating the potential of technology-driven approaches to increase speed, quality, and scalability of drug discovery.
• Management believes the company's existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months.
• The company anticipates needing to raise additional financing in the future to fund operations, including potential commercialization of any approved product candidates.

Industry Context

Recursion Pharmaceuticals operates in the rapidly evolving TechBio sector, aiming to industrialize drug discovery through its AI-driven Recursion Operating System (OS). The company differentiates itself by building a 'full-stack platform' that integrates both wet-lab and dry-lab capabilities in-house, creating a virtuous cycle of iteration. This contrasts with many competitors who rely on 'point solutions' for specific steps in drug discovery or are solely focused on either wet-lab (traditional biotech/pharma) or dry-lab (facing commoditized algorithms and non-proprietary data challenges). The company's strategic partnerships with major biopharmaceutical companies like Roche-Genentech, Sanofi, Bayer, and Merck KGaA, along with its technology and data-focused collaborations, underscore its ambition to lead in AI-enabled drug discovery and development.

Comparison to Industry Standards

• Recursion positions itself as a 'full-stack platform' provider, integrating wet-lab and dry-lab capabilities, which it believes differentiates it from traditional biotech/pharma companies (wet-lab only) and other AI-driven companies (dry-lab only with commoditized algorithms).
• The company's approach aims to reduce the time and cost and increase the likelihood of success in drug discovery relative to the traditional paradigm, though specific comparative metrics against industry benchmarks or named competitors' projects are not provided in the filing.
• The acquisition of Exscientia and the ongoing collaborations with major pharmaceutical companies (Sanofi, Roche, Merck KGaA, Bayer) suggest a strategy to build a comprehensive pipeline and leverage external expertise, a common model in the biopharma industry for risk sharing and accelerating development.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action complaint (Campanile v. Exscientia plc, Case No. 1:24-cv-05692, consolidated with 1:24-cv-07181) was filed against Exscientia plc and certain individuals, alleging violations of federal securities laws by making materially false and misleading statements. A motion to dismiss was filed on January 21, 2025, and remains pending. No liability recorded as an unfavorable outcome was not probable as of June 30, 2025.
• A lawsuit was filed by Industry Office SLC, LLC against the company (Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc., Case No. 230904627) alleging anticipatory repudiation, breach of contract, and breach of implied covenant of good faith and fair dealing related to a lease agreement. The company filed counterclaims alleging breach of contract and fraudulent misrepresentation. Discovery is ongoing, and no liability was recorded as an unfavorable outcome was not probable as of June 30, 2025.

Related Party Transactions

• Christopher Gibson, CEO and President, and a member of the Board of Directors, terminated a Rule 10b5-1 trading arrangement previously adopted in December 2024 and adopted a subsequent Rule 10b5-1 trading arrangement on May 12, 2025, for the sale of up to 86,634 shares of Class A common stock and potential conversion and sale of up to 4,247,433 shares of Class B common stock.

Stakeholder Impact

• Shareholders: Experienced significant net losses and increased cash burn, but also potential for future value creation through pipeline advancements and strategic partnerships. Potential for dilution from ongoing ATM offerings.
• Employees: Impacted by a workforce reduction of approximately 20% in June 2025, leading to severance payments and potential changes in roles and responsibilities.
• Customers/Partners: Continued advancement of collaborative programs with Sanofi, Roche & Genentech, Bayer, and Merck KGaA, indicating ongoing commitment to these partnerships.
• Patients: Progress in clinical and preclinical programs (e.g., REC-1245, REC-617, REC-102) offers potential for new therapeutic options in oncology and rare diseases.

Next Steps

• Present additional preclinical data from the REC-102 program at the 2025 American Society for Bone and Mineral Research (ASMBR) on September 6, 2025.
• Expect additional data in FAP from the TUPELO study for REC-4881 (MEK1/2) in 2H25.
• Expect additional monotherapy data for REC-617 (CDK7) in 2H25.
• Expect a development candidate for REC-7735 (PI3K H1047R) in 2H25.
• Expect early Phase 1 safety and PK monotherapy data for REC-1245 (RBM39) in 1H26.
• Expect Phase 1 initiation for REC-102 (ENPP1) in 2H26.
• Expect early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) in 2H26.
• Potential for over $100 million in partnership milestones by the end of 2026.
• Several programs are advancing towards potential development candidate designation over the next 12-15 months.
• Continue to finalize the purchase price allocation for the Exscientia acquisition no later than one year from the acquisition date.
• Continue remediation actions for the material weakness in internal control over financial reporting.

Key Dates

Recommendation

Recursion Pharmaceuticals is in a high-growth, high-risk phase, characterized by significant R&D investments and widening losses, which are typical for a clinical-stage TechBio company. While the substantial increase in net loss and cash burn is a concern, the company's strategic acquisitions (Exscientia), robust pipeline advancements (REC-102, REC-617), and strong partnerships with major pharmaceutical players (Sanofi, Roche, Merck KGaA) demonstrate progress in its long-term strategy to industrialize drug discovery. The ongoing ATM offering provides a capital runway for at least 12 months, but the explicit need for future financing indicates continued dilution risk. The material weakness in internal controls is a governance concern, but remediation is underway. Given the high-risk, high-reward nature of drug discovery and the current financial trajectory, a 'hold' recommendation is appropriate for investors who are already positioned, acknowledging both the significant burn rate and the long-term potential of its AI-driven platform and pipeline.

Keywords

Biotechnology, AI drug discovery, Pharmaceuticals, Oncology, Rare disease, Machine learning, Drug development, TechBio, SEC filing, 10-Q, Clinical stage, R&D, Exscientia, Tempus, Sanofi, Roche, Merck KGaA